|Day Low/High||41.76 / 42.35|
|52 Wk Low/High||37.59 / 67.34|
The Auvi-Q was released Feb. 14, but it's unclear whether patients will break up with their current option, EpiPen, for something new.
The most recent short interest data has been released for the 01/31/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
GlaxoSmithKline beat analysts' expectations for fourth-quarter sales and earnings Wednesday but warned of a significant hit this year from anticipated generic competition to its Advair asthma treatment.
Mylan settled a pay-for-delay lawsuit over its narcolepsy drug, but its share prices are falling.
Prices look set to test key resistance, and this time should see a breakout to the upside.
Generics for drugs facing shortages or having few manufacturers is bill's focus.
Mylan's shares rose after Teva's claims of patent infringement were rejected, despite the announcement that the FTC is investigating the drugmaker for antitrust violations.
The drug company saw its stock climb 3% Tuesday on news that it can move ahead with generic Copaxone.
Mylan, Momenta Pharmaceuticals and Seres Therapeutics were among the biotech stock movers in premarket trading on Tuesday.
It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.
The autoinjector will be free for insured patients and those whose annual income is less than $100,000.
Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.
The drug maker's shares have fallen 6.2% since Wednesday's market open.
The stock has taken a beating, but users of Afrezza are loyal to the drug.
An appeals court in Indiana upheld Eli Lilly's patent regarding Alimta, a major cancer drug for Lilly, keeping Teva and other generic drug specialists at bay.
The price of EpiPens has surged about 25% annually since 2007.
Health insurance giant Cigna said it will no longer cover Mylan's EpiPen.
Cigna will now encourage patients to use either Impax's or Mylan's generic autoinjector. Impax offers cheaper prices, but can its manufacturing keep up?
Donald Trump continued to rip corporate America at a press conference Wednesday, but what else did you missy?
Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.
If Approved, MYL-1401O Has Potential To Be the First Biosimilar Trastuzumab in the U.S.
Cold-Eeze will become Mylan's largest U.S. over-the-counter brand franchise, and builds upon its $1 billion global OTC business.